The USPTO granted patent US12594266B2 to SCYNEXIS, INC. for triterpenoid antifungal compounds derived from eufumafungin, which demonstrate unexpected efficacy against Pneumocystis spp. and can reduce lung burden of both cyst and trophic fungal forms. The compounds function as (1,3)-β-D-glucan synthesis inhibitors with potent in vivo activity, adequate lung tissue penetration, and favorable tolerability profiles. The 16-claim patent covers the compound structures, pharmaceutical formulations, and methods of use for treating or preventing PCP.

Affected parties including pharmaceutical companies, drug manufacturers, and researchers developing antifungal therapies should monitor this intellectual property grant as it may restrict freedom to operate in the PCP antifungal treatment space. Generic or biosimilar developers seeking to commercialize triterpenoid-based antifungals for Pneumocystis pneumonia will need to evaluate licensing options or design-around strategies to avoid infringing the granted claims.